NCT02600351 - Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2015

Primary Completion Date

March 21, 2017

Study Completion Date

May 29, 2017

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily

DRUG

RBV

Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (42)

10025

New York

10032

New York

10467

The Bronx

19141

Philadelphia

21045

Columbia

21202

Baltimore

22908

Charlottesville

27599

Chapel Hill

27710

Durham

28204

Charlotte

33331

Weston

33777

Largo

37232

Nashville

38104

Memphis

43212

Columbus

44109

Cleveland

55114

Saint Paul

60076

Skokie

60612

Chicago

63110

St Louis

64131

Kansas City

72205

Little Rock

75203

Dallas

75246

Dallas

75390

Dallas

77030

Houston

78758

Austin

84132

Salt Lake City

90027

Los Angeles

91105

Pasadena

92377

Rialto

93003

Ventura

95817

Sacramento

98101

Seattle

98122

Seattle

06520

New Haven

01655

Worcester

08234

Egg Harbor

V5Z 1H2

Vancouver

H2L 4P9

Montreal

H4A 3J1

Montreal

00716

Ponce